Steven R. Tannenbaum

In 1973 Tannenbaum did a sabbatical at the Hebrew University of Jerusalem, where he decided to switch his career into cancer research at the suggestion of Gerald Wogan.

Tannenbaum’s areas of research include mechanisms of biochemical activation of chemicals to electrophilic forms that bind to DNA and proteins; application of biomarkers to the prediction of the severity of inflammatory disease; the role of endogenous nitric oxide in inflammation, cytotoxicity, and DNA damage; and development of new tools for drug metabolism, pharmacokinetics, and toxicology.

Current research focuses on the causes of IBD, prognostic biomarkers for Dengue fever, human microphysiological systems for drug safety and PK/PD, and the role of nitric oxide in brain pathology, including Alzheimer’s Disease and ASD.

The Tannenbaum laboratory has made important contributions to the etiology of cancer from both environmental and endogenous factors.

His laboratory also collaborated with Linda Griffith in the development of the LiverChip, a microphysiological, immunocompetent, flow-through human liver bioreactor.